Eli Lilly and Co (LLY.N)
53.50USD
4:00pm EDT
$0.39 (+0.73%)
$53.11
$53.37
$53.66
$53.12
865,191
1,402,936
$58.40
$42.10
About
Overall
| Beta: | 0.75 |
| Market Cap (Mil.): | $59,835.73 |
| Shares Outstanding (Mil.): | 1,126.64 |
| Dividend: | 0.49 |
| Yield (%): | 3.69 |
Financials
| LLY.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 11.91 | 37.93 | 37.76 |
| EPS (TTM): | 4.46 | -- | -- |
| ROI: | 19.63 | 19.48 | 18.76 |
| ROE: | 33.23 | 20.17 | 19.59 |
WRAPUP 1-Drugmakers fear short-term "turmoil" as China probes widen
* AstraZeneca CEO sees short-term disruption, price pressure
Eli Lilly to freeze employee base pay ahead of generic onslaught
NEW YORK - U.S. drugmaker Eli Lilly & Co , which expects to lose about 20 percent of its global revenue next year due to the expiration of key drug patents, is suspending base pay increases for most employees in 2014 to cut costs.
Medicare plan on Alzheimer's test dismays advocates
CHICAGO - Alzheimer's experts plan to protest proposed Medicare guidelines that would deny coverage of an Eli Lilly diagnostic test for the disease unless patients are taking part one of several clinical trials in which the $3,000 test is being used.
UPDATE 1-Medicare plan on Alzheimer's test dismays advocates
CHICAGO, July 9 - Alzheimer's experts plan to protest proposed Medicare guidelines that would deny coverage of an Eli Lilly diagnostic test for the disease unless patients are taking part one of several clinical trials in which the $3,000 test is being used.
Lilly CEO returns to work after surgery
July 8 - Eli Lilly and Co said Chief Executive John Lechleiter returned to work after recovering from a surgery to treat a dilated aorta.
FDA probes deaths of two patients on Lilly schizophrenia drug
- The Food and Drug Administration is investigating the cases of two individuals who died after injections with Eli Lilly and Co's long-acting treatment for schizophrenia, Zyprexa Relprevv.
Lilly CEO recovering after repair to aorta
- John Lechleiter, the longtime chief executive of Eli Lilly and Co, is recovering from successful surgery to repair a dilated aorta, the U.S. drugmaker said on Tuesday.
UPDATE 1-Eli Lilly lymphoma drug fails in late-stage trial
May 10 - Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.
Lilly CEO Lechleiter to undergo surgery for dilated aorta
- Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to work by this summer.
Lilly profit beats forecast, helped by lower taxes
- Eli Lilly and Co on Wednesday reported higher-than-expected first-quarter earnings, helped by favorable taxes and higher sales of its treatments for diabetes, depression and lung cancer.
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +28.50 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Abbott Laboratories (ABT.N) | $36.84 | +0.21 |
| Bristol Myers Squibb Co. (BMY.N) | $43.99 | +0.75 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
| AstraZeneca plc (AZN.L) | 3,334.00p | -1.00 |
| Sanofi SA (SASY.PA) | €76.85 | -3.32 |
| Amgen, Inc. (AMGN.OQ) | $109.45 | +1.16 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Wright Reports
|
$483.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

